Sterility Testing Workflow | GMPify Training

🧪

Sterility Testing - A Statistical Sample, Not a Sterility Guarantee

USP <71> sterility testing verifies the absence of viable microorganisms in a defined sample drawn from a batch. Because the test examines only a small fraction of the total batch, a passing result reduces the statistical probability of contamination but cannot itself prove the entire batch is sterile. Sterility assurance depends on the validated manufacturing process, environmental monitoring, and process controls working together with the sterility test as one verification point among several, not as a stand-alone guarantee.

USP <71> · USP <1071> · EU GMP Annex 1 2022 · 21 CFR 211.167 · PDA TR 33

USP <71>

USP <1071>

EU GMP Annex 1 2022

21 CFR 211.167

PDA TR 33

Membrane Filtration

Preferred method under USP <71> whenever product characteristics allow it. Product is filtered through a membrane that retains microorganisms, which are then cultured directly on the filter in media.

Use case: Filterable products

Advantage: Removes inhibitory substances

Status: Preferred method

Direct Inoculation

Alternative method used when the product cannot be filtered. Sample is added directly to the growth media, requiring demonstration that any antimicrobial activity is neutralized.

Use case: Non-filterable products

Requirement: Neutralization confirmed

Status: Alternative method

Sample Size Requirements

Minimum number of containers and quantity from each tested per USP <71> Table 3, scaled to batch size, with larger batches requiring larger sample sizes.

Basis: USP <71> Table 3

Scaling: By batch size

Minimum containers: 10 (small batch)

Incubation Conditions

Dual media system incubated for a minimum of 14 days at two different temperature ranges to support recovery of both bacteria and fungi.

FTM: 30-35C, 14 days

TSB: 20-25C, 14 days

Minimum duration: 14 days

Phase 1

Sample Selection and Preparation

1Determine required sample size

Number of containers and quantity per container calculated from batch size using USP <71> Table 3, ensuring the sample represents the batch and any known risk areas such as beginning, middle, and end of fill.

USP <71> Table 3

↓

2Select the test method

Membrane filtration selected wherever product characteristics permit. Direct inoculation used only when filtration is not feasible, with neutralization of antimicrobial activity confirmed beforehand.

USP <71>

↓

3Confirm method suitability

Method suitability testing performed prior to routine use, demonstrating the product does not inhibit growth of challenge organisms under the chosen test conditions.

USP <71> · USP <1071>

↓

4Prepare samples aseptically

Sample preparation and testing performed in an ISO 5 environment using validated aseptic technique, with the testing environment itself monitored to rule out false positives from the lab.

USP <71> · EU GMP Annex 1 2022

Phase 2

Test Execution

5Filter or inoculate into dual media

Samples filtered or inoculated into both Fluid Thioglycollate Medium and Soybean-Casein Digest Medium to support recovery of aerobic, anaerobic, and fungal organisms.

USP <71>

↓

6Incubate for a minimum of 14 days

FTM incubated at 30 to 35 degrees C, TSB incubated at 20 to 25 degrees C, both for a minimum of 14 days with periodic visual examination for turbidity indicating growth.

USP <71>

↓

7Run positive and negative controls

Positive control confirms media growth-promoting capability. Negative control confirms the absence of contamination introduced by the testing process itself.

USP <71>

↓

Is growth observed in any test article container?

YES → Initiate investigation NO → Proceed to interpretation

Phase 3

Result Interpretation and Investigation

8Confirm full incubation with no growth

A pass result requires no evidence of microbial growth across the complete minimum 14-day incubation period in both media, with controls performing as expected.

USP <71>

↓

9Investigate any growth as a potential OOS

Growth in a test article triggers a full laboratory and manufacturing investigation per USP <1071> before a result can be invalidated, including organism identification and assessment of whether the finding is laboratory or product related.

USP <1071> · 21 CFR 211.192

↓

10Correlate with environmental monitoring data

EM data from the fill operation reviewed alongside the sterility test result. Environmental excursions during fill strengthen or weaken the case for a product-related versus laboratory-related finding.

PDA TR 33 · EU GMP Annex 1 2022

Phase 4

Release Decision and Documentation

11QA review of the complete test package

Quality unit reviews raw data, control results, method suitability documentation, and any investigation records associated with the sterility test before a release decision is made.

21 CFR 211.22

↓

12Correlate sterility result with process controls

Batch release decision considers the sterility test result alongside process validation status, environmental monitoring trends, and any deviations occurring during the batch's manufacture.

21 CFR 211.167 · EU GMP Annex 1 2022

↓

13Retain complete documentation

Test records, chain of custody, incubation logs, and any investigation documentation retained per site record retention requirements and available for inspection.

21 CFR 211.180

Test Parameters (USP <71>)

Sample Size by Batch

Minimum 10 containers for batches up to 100 containers, scaling upward per USP <71> Table 3 as batch size increases. Larger sample sizes provide greater statistical confidence.

USP <71> Table 3

Minimum Incubation Period

14 days minimum for both media types, with no reduction in incubation time regardless of when visual clarity is achieved, unless supported by validated rapid methods.

USP <71>

Method Suitability Requirement

Required before routine testing begins and repeated whenever the product formulation, container, or test method changes in a way that could affect recovery.

USP <71> · USP <1071>

Growth Investigation Response Steps

Step 1 - Secure and isolate the positive result Segregate the affected containers and preserve all associated documentation before any further handling.

Step 2 - Identify the recovered organism Species-level identification helps distinguish a likely environmental or personnel-related contaminant from an organism suggestive of a process failure.

Step 3 - Review laboratory practices and environment Assess testing environment monitoring data, analyst technique, and equipment for any laboratory-related root cause per USP <1071>.

Step 4 - Review manufacturing and fill data Cross-reference environmental monitoring, personnel monitoring, and process parameters from the batch's fill operation.

Step 5 - Reach a documented conclusion Conclude whether the result is invalidated as laboratory related or confirmed as a true positive requiring batch rejection, with the rationale fully documented.

Sampling Requirements

Representative fill positions Samples drawn to represent the beginning, middle, and end of the fill run wherever practical, capturing any risk associated with extended fill duration.

Chain of custody maintained Sample handling from collection through testing documented to demonstrate containers were not compromised prior to testing.

Container integrity verified Test article containers inspected for integrity before testing, since a compromised container could produce a false positive unrelated to the manufacturing process.

Retained samples Sufficient additional samples retained where practical to support any repeat testing required by an investigation.

Method Verification and Control Requirements

Method Suitability Test Demonstrates the chosen test method and any product-specific neutralization step do not inhibit recovery of low levels of challenge microorganisms.

Positive Control Confirms both media formulations remain capable of supporting growth of viable microorganisms at the time of use.

Negative Control Confirms the testing process itself, including the environment, equipment, and analyst technique, did not introduce contamination.

Growth Promotion Testing Each lot of FTM and TSB media undergoes growth promotion testing before use in sterility testing to confirm media quality.

Testing Environment Monitoring The ISO 5 environment where testing is performed is itself monitored, providing data used to help distinguish laboratory contamination from product contamination.

Analyst Qualification Analysts performing sterility testing are qualified through documented gowning and aseptic technique demonstration before performing routine testing.

Equipment Qualification Filtration units, incubators, and isolators or RABS used for testing are qualified and undergo routine calibration and preventive maintenance.

Rapid Sterility Method Validation Where alternative rapid sterility methods are used in place of the compendial 14-day method, the method is validated for equivalence per USP <1071> before implementation.

Never do this

Treat a passing sterility test as a stand-alone guarantee of batch sterility. Reduce incubation time below 14 days without a validated rapid method. Invalidate a positive result without a complete documented investigation. Skip method suitability testing when the product formulation changes.

Membrane filtration vs direct inoculation

Membrane filtration is preferred because it physically removes inhibitory substances that could otherwise mask growth. Direct inoculation is reserved for products that cannot be filtered and requires demonstrated neutralization of antimicrobial activity.

Test result vs process control

The sterility test is one verification point among several. Process validation, aseptic technique, and environmental monitoring together provide the sterility assurance that the test alone cannot statistically guarantee.

Key regulations

USP <71> - sterility test methodology. USP <1071> - rapid methods and OOS investigation guidance. EU GMP Annex 1 2022 - sterility assurance expectations. 21 CFR 211.167 - special testing requirements. PDA TR 33 - sterility test method evaluation.